Jiangxin Xu (Zhifei Xu)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 17

Top Topics

Tyrosine Kinase

Epidermal Growth Factor Receptor

Chronic Myeloid Leukemia

Top Venues

Expert opinion on therapeutic targets

Nature communications

Expert opinion on drug metabolism & toxicology

Expert review of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Mengting Cheng, Xinyu Tao, Fei Wang, Nonger Shen, Jiangxin Xu, Yuhuai Hu, Ping Huang, Peihua Luo, Qiaojun He, Yiwen Zhang, Fangjie Yan
Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma. Expert opinion on drug metabolism & toxicology (2024)
Yiming Yin, Yourong Zhou, Xiaochun Yang, Jiangxin Xu, Bo Yang, Peihua Luo, Hao Yan, Qiaojun He
The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets. Expert opinion on therapeutic targets 27 (1) (2023)
Yiming Yin, Yourong Zhou, Xiaochun Yang, Jiangxin Xu, Bo Yang, Peihua Luo, Hao Yan, Qiaojun He
The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets. Expert opinion on therapeutic targets (2023)
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Jiangxin Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature communications 14 (1) (2023)
Yiming Yin, Yourong Zhou, Xiaochun Yang, Jiangxin Xu, Bo Yang, Peihua Luo, Hao Yan, Qiaojun He
The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets. Expert opinion on therapeutic targets 27 (1) (2023)
Yiming Yin, Yourong Zhou, Xiaochun Yang, Jiangxin Xu, Bo Yang, Peihua Luo, Hao Yan, Qiaojun He
The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets. Expert opinion on therapeutic targets 27 (1) (2023)
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Jiangxin Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature communications 14 (1) (2023)
Yiming Yin, Yourong Zhou, Xiaochun Yang, Jiangxin Xu, Bo Yang, Peihua Luo, Hao Yan, Qiaojun He
The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets. Expert opinion on therapeutic targets (2023)
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Jiangxin Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature communications 14 (1) (2023)
Hao Yan, Xiangliang Huang, Jiangxin Xu, Ying Zhang, Jiajia Chen, Zhifei Xu, Hui Li, Zeng Wang, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Chloroquine Intervenes Nephrotoxicity of Nilotinib through Deubiquitinase USP13-Mediated Stabilization of Bcl-XL. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Yourong Zhou, Yiming Yin, Jiangxin Xu, Jiangxin Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan, Xiaochun Yang
An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer. Expert opinion on pharmacotherapy (2023)
Zeng Wang, Liyu Jiang, Hao Yan, Jiangxin Xu, Peihua Luo
Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. Expert review of clinical pharmacology 14 (4) (2021)
Jiangxia Du, Hao Yan, Jiangxin Xu, Bo Yang, Qiaojun He, Xiaohong Wang, Peihua Luo
Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors. Expert opinion on drug metabolism & toxicology 17 (11) (2021)
Jiangxin Xu, Ying Jin, Zizheng Gao, Yan Zeng, Jiangxia Du, Hao Yan, Xueqin Chen, Li Ping, Nengming Lin, Bo Yang, Qiaojun He, Peihua Luo
Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. Autophagy (2021)
Liyu Jiang, Li Ping, Hao Yan, Xiaochun Yang, Qiaojun He, Jiangxin Xu, Peihua Luo
Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. Expert opinion on drug metabolism & toxicology 16 (9) (2020)
Leilei Ai, Liyu Jiang, Jiangxin Xu, Hao Yan, Peihua Luo, Qiaojun He
COVID-19 epidemic: a special focus on diagnosis, complications, and management. Expert review of clinical pharmacology 13 (10) (2020)
Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Jiangxin Xu, Xiaochun Yang
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug design, development and therapy 14 (2020)